Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 387

1.

Reducing setting time of blended cement paste containing high-SO3 fly ash (HSFA) using chemical/physical accelerators and by fly ash pre-washing.

Zunino F, Bentz DP, Castro J.

Cem Concr Compos. 2018 Jul;90:14-26. doi: 10.1016/j.cemconcomp.2018.03.018. Epub 2018 Mar 20.

2.

c-MYC G-quadruplex binding by the RNA polymerase I inhibitor BMH-21 and analogues revealed by a combined NMR and biochemical Approach.

Musso L, Mazzini S, Rossini A, Castagnoli L, Scaglioni L, Artali R, Di Nicola M, Zunino F, Dallavalle S.

Biochim Biophys Acta Gen Subj. 2018 Mar;1862(3):615-629. doi: 10.1016/j.bbagen.2017.12.002. Epub 2017 Dec 8.

PMID:
29229300
3.

Low-Temperature Curing Strength Enhancement in Cement-Based Materials Containing Limestone Powder.

Bentz DP, Stutzman PE, Zunino F.

Mater Struct. 2017 Jun;50(3). pii: 173. doi: 10.1617/s11527-017-1042-6. Epub 2017 Apr 28.

4.

Microenvironment modulation and enhancement of antilymphoma therapy by the heparanase inhibitor roneparstat.

Rossini A, Zunino F, Ruggiero G, De Cesare M, Cominetti D, Tortoreto M, Lanzi C, Cassinelli G, Zappasodi R, Tripodo C, Gulino A, Zaffaroni N, Di Nicola M.

Hematol Oncol. 2018 Feb;36(1):360-362. doi: 10.1002/hon.2466. Epub 2017 Jul 21. No abstract available.

PMID:
28730742
5.

Limestone and Silica Powder Replacements for Cement: Early-Age Performance.

Bentz DP, Ferraris CF, Jones SZ, Lootens D, Zunino F.

Cem Concr Compos. 2017 Apr;78:43-56. doi: 10.1016/j.cemconcomp.2017.01.001. Epub 2017 Jan 5.

6.

Chemical vs. Physical Acceleration of Cement Hydration.

Bentz DP, Zunino F, Lootens D.

Concr Int. 2016 Nov;38(11):37-44.

7.

Synthesis and Evaluation of New Naphthalene and Naphthoquinone Derivatives as Anticancer Agents.

Beretta GL, Ribaudo G, Menegazzo I, Supino R, Capranico G, Zunino F, Zagotto G.

Arch Pharm (Weinheim). 2017 Jan;350(1). doi: 10.1002/ardp.201600286. Epub 2016 Dec 19.

PMID:
27990691
8.

Antitumor efficacy of the heparan sulfate mimic roneparstat (SST0001) against sarcoma models involves multi-target inhibition of receptor tyrosine kinases.

Cassinelli G, Favini E, Dal Bo L, Tortoreto M, De Maglie M, Dagrada G, Pilotti S, Zunino F, Zaffaroni N, Lanzi C.

Oncotarget. 2016 Jul 26;7(30):47848-47863. doi: 10.18632/oncotarget.10292.

9.

3-Arylidene-N-hydroxyoxindoles: A New Class of Compounds Endowed with Antitumor Activity.

Musso L, Cincinelli R, Zuco V, De Cesare M, Zunino F, Fallacara AL, Botta M, Dallavalle S.

ChemMedChem. 2016 Aug 19;11(16):1700-4. doi: 10.1002/cmdc.201600225. Epub 2016 Jun 17.

10.

Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity.

Cincinelli R, Zwick V, Musso L, Zuco V, De Cesare M, Zunino F, Simoes-Pires C, Nurisso A, Giannini G, Cuendet M, Dallavalle S.

Eur J Med Chem. 2016 Apr 13;112:99-105. doi: 10.1016/j.ejmech.2016.02.001. Epub 2016 Feb 3.

11.

New macrocyclic analogs of the natural histone deacetylase inhibitor FK228; design, synthesis and preliminary biological evaluation.

Ni M, Esposito E, Raj VP, Muzi L, Zunino F, Zuco V, Cominetti D, Penco S, Dal Pozzo A.

Bioorg Med Chem. 2015 Nov 1;23(21):6785-93. doi: 10.1016/j.bmc.2015.10.004. Epub 2015 Oct 9. Review.

PMID:
26481659
12.

Investigation on the ZBG-functionality of phenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase inhibitors.

Musso L, Cincinelli R, Zuco V, Zunino F, Nurisso A, Cuendet M, Giannini G, Vesci L, Pisano C, Dallavalle S.

Bioorg Med Chem Lett. 2015 Oct 15;25(20):4457-60. doi: 10.1016/j.bmcl.2015.09.006. Epub 2015 Sep 5.

PMID:
26376355
13.

Perspectives in the development of hybrid bifunctional antitumour agents.

Musso L, Dallavalle S, Zunino F.

Biochem Pharmacol. 2015 Aug 15;96(4):297-305. doi: 10.1016/j.bcp.2015.06.006. Epub 2015 Jun 11. Review.

14.

Targeting the invasive phenotype of cisplatin-resistant non-small cell lung cancer cells by a novel histone deacetylase inhibitor.

Zuco V, Cassinelli G, Cossa G, Gatti L, Favini E, Tortoreto M, Cominetti D, Scanziani E, Castiglioni V, Cincinelli R, Giannini G, Zunino F, Zaffaroni N, Lanzi C, Perego P.

Biochem Pharmacol. 2015 Mar 15;94(2):79-90. doi: 10.1016/j.bcp.2015.01.002. Epub 2015 Jan 16.

PMID:
25600908
15.

Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.

Cincinelli R, Musso L, Giannini G, Zuco V, De Cesare M, Zunino F, Dallavalle S.

Eur J Med Chem. 2014 May 22;79:251-9. doi: 10.1016/j.ejmech.2014.04.021. Epub 2014 Apr 8.

16.

Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas.

Zappasodi R, Cavanè A, Iorio MV, Tortoreto M, Guarnotta C, Ruggiero G, Piovan C, Magni M, Zaffaroni N, Tagliabue E, Croce CM, Zunino F, Gianni AM, Di Nicola M.

Int J Cancer. 2014 Nov 1;135(9):2034-45. doi: 10.1002/ijc.28852. Epub 2014 Mar 26. Erratum in: Int J Cancer. 2017 Nov 1;141(9):E6.

17.

Differential outcome of MEK1/2 inhibitor-platinum combinations in platinum-sensitive and -resistant ovarian carcinoma cells.

Cossa G, Lanzi C, Cassinelli G, Carenini N, Arrighetti N, Gatti L, Corna E, Zunino F, Zaffaroni N, Perego P.

Cancer Lett. 2014 Jun 1;347(2):212-24. doi: 10.1016/j.canlet.2014.02.016. Epub 2014 Feb 24.

PMID:
24576622
18.

The potential of heparanase as a therapeutic target in cancer.

Pisano C, Vlodavsky I, Ilan N, Zunino F.

Biochem Pharmacol. 2014 May 1;89(1):12-9. doi: 10.1016/j.bcp.2014.02.010. Epub 2014 Feb 22.

19.

7-Azaindole-1-carboxamides as a new class of PARP-1 inhibitors.

Cincinelli R, Musso L, Merlini L, Giannini G, Vesci L, Milazzo FM, Carenini N, Perego P, Penco S, Artali R, Zunino F, Pisano C, Dallavalle S.

Bioorg Med Chem. 2014 Feb 1;22(3):1089-103. doi: 10.1016/j.bmc.2013.12.031. Epub 2013 Dec 22.

20.

Improved apoptotic cell death in drug-resistant non-small-cell lung cancer cells by tumor necrosis factor-related apoptosis-inducing ligand-based treatment.

Gatti L, Cossa G, Tinelli S, Carenini N, Arrighetti N, Pennati M, Cominetti D, De Cesare M, Zunino F, Zaffaroni N, Perego P.

J Pharmacol Exp Ther. 2014 Mar;348(3):360-71. doi: 10.1124/jpet.113.210054. Epub 2013 Dec 17.

PMID:
24345465
21.

Synergistic antitumor activity of cetuximab and namitecan in human squamous cell carcinoma models relies on cooperative inhibition of EGFR expression and depends on high EGFR gene copy number.

De Cesare M, Lauricella C, Veronese SM, Cominetti D, Pisano C, Zunino F, Zaffaroni N, Zuco V.

Clin Cancer Res. 2014 Feb 15;20(4):995-1006. doi: 10.1158/1078-0432.CCR-13-1684. Epub 2013 Dec 10.

22.

Quinazolinecarboline alkaloid evodiamine as scaffold for targeting topoisomerase I and sirtuins.

Christodoulou MS, Sacchetti A, Ronchetti V, Caufin S, Silvani A, Lesma G, Fontana G, Minicone F, Riva B, Ventura M, Lahtela-Kakkonen M, Jarho E, Zuco V, Zunino F, Martinet N, Dapiaggi F, Pieraccini S, Sironi M, Dalla Via L, Gia OM, Passarella D.

Bioorg Med Chem. 2013 Nov 15;21(22):6920-8. doi: 10.1016/j.bmc.2013.09.030. Epub 2013 Sep 19.

PMID:
24103429
23.

Design, modeling, synthesis and biological activity evaluation of camptothecin-linked platinum anticancer agents.

Cincinelli R, Musso L, Dallavalle S, Artali R, Tinelli S, Colangelo D, Zunino F, De Cesare M, Beretta GL, Zaffaroni N.

Eur J Med Chem. 2013 May;63:387-400. doi: 10.1016/j.ejmech.2013.02.022. Epub 2013 Mar 1.

24.

Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models.

Cassinelli G, Lanzi C, Tortoreto M, Cominetti D, Petrangolini G, Favini E, Zaffaroni N, Pisano C, Penco S, Vlodavsky I, Zunino F.

Biochem Pharmacol. 2013 May 15;85(10):1424-32. doi: 10.1016/j.bcp.2013.02.023. Epub 2013 Mar 1.

PMID:
23466421
25.

Camptothecin-7-yl-methanthiole: semisynthesis and biological evaluation.

Christodoulou MS, Zunino F, Zuco V, Borrelli S, Comi D, Fontana G, Martinelli M, Lorens JB, Evensen L, Sironi M, Pieraccini S, Dalla Via L, Gia OM, Passarella D.

ChemMedChem. 2012 Dec;7(12):2134-43. doi: 10.1002/cmdc.201200322. Epub 2012 Oct 19.

PMID:
23086693
26.

Sulfonates-PMMA nanoparticles conjugates: a versatile system for multimodal application.

Monasterolo C, Ballestri M, Sotgiu G, Guerrini A, Dambruoso P, Sparnacci K, Laus M, De Cesare M, Pistone A, Beretta GL, Zunino F, Benfenati V, Varchi G.

Bioorg Med Chem. 2012 Nov 15;20(22):6640-7. doi: 10.1016/j.bmc.2012.09.023. Epub 2012 Sep 21.

PMID:
23043726
27.

Design, synthesis, and biological evaluation of novel cRGD-paclitaxel conjugates for integrin-assisted drug delivery.

Pilkington-Miksa M, Arosio D, Battistini L, Belvisi L, De Matteo M, Vasile F, Burreddu P, Carta P, Rassu G, Perego P, Carenini N, Zunino F, De Cesare M, Castiglioni V, Scanziani E, Scolastico C, Casiraghi G, Zanardi F, Manzoni L.

Bioconjug Chem. 2012 Aug 15;23(8):1610-22. doi: 10.1021/bc300164t. Epub 2012 Jul 20.

PMID:
22770429
28.

Development and therapeutic impact of HDAC6-selective inhibitors.

Dallavalle S, Pisano C, Zunino F.

Biochem Pharmacol. 2012 Sep 15;84(6):756-65. doi: 10.1016/j.bcp.2012.06.014. Epub 2012 Jun 21. Review.

PMID:
22728920
29.

Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.

Gatti L, Benedetti V, De Cesare M, Corna E, Cincinelli R, Zaffaroni N, Zunino F, Perego P.

J Inorg Biochem. 2012 Aug;113:94-101. doi: 10.1016/j.jinorgbio.2012.04.007. Epub 2012 Apr 27.

PMID:
22717676
30.

REST controls self-renewal and tumorigenic competence of human glioblastoma cells.

Conti L, Crisafulli L, Caldera V, Tortoreto M, Brilli E, Conforti P, Zunino F, Magrassi L, Schiffer D, Cattaneo E.

PLoS One. 2012;7(6):e38486. doi: 10.1371/journal.pone.0038486. Epub 2012 Jun 11. Erratum in: PLoS One. 2015;10(9):e0139645.

31.

Isoxazolo(aza)naphthoquinones: a new class of cytotoxic Hsp90 inhibitors.

Bargiotti A, Musso L, Dallavalle S, Merlini L, Gallo G, Ciacci A, Giannini G, Cabri W, Penco S, Vesci L, Castorina M, Milazzo FM, Cervoni ML, Barbarino M, Pisano C, Giommarelli C, Zuco V, De Cesare M, Zunino F.

Eur J Med Chem. 2012 Jul;53:64-75. doi: 10.1016/j.ejmech.2012.03.036. Epub 2012 Mar 28.

PMID:
22538015
32.

The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects.

Cassinelli G, Zuco V, Petrangolini G, De Cesare M, Tortoreto M, Lanzi C, Cominetti D, Zaffaroni N, Orlandi A, Passeri D, Meco D, Di Francesco AM, Riccardi R, Bucci F, Pisano C, Zunino F.

Biochem Pharmacol. 2012 Jul 15;84(2):163-71. doi: 10.1016/j.bcp.2012.04.005. Epub 2012 Apr 13.

PMID:
22525722
33.

Synergistic antitumor effects of novel HDAC inhibitors and paclitaxel in vitro and in vivo.

Zuco V, De Cesare M, Cincinelli R, Nannei R, Pisano C, Zaffaroni N, Zunino F.

PLoS One. 2011;6(12):e29085. doi: 10.1371/journal.pone.0029085. Epub 2011 Dec 14.

34.

Sensitization of tumor cells by targeting histone deacetylases.

Perego P, Zuco V, Gatti L, Zunino F.

Biochem Pharmacol. 2012 Apr 15;83(8):987-94. doi: 10.1016/j.bcp.2011.11.010. Epub 2011 Nov 22. Review.

PMID:
22120677
35.

Role of tyrosyl-DNA phosphodiesterase 1 and inter-players in regulation of tumor cell sensitivity to topoisomerase I inhibition.

Perego P, Cossa G, Tinelli S, Corna E, Carenini N, Gatti L, De Cesare M, Ciusani E, Zunino F, Luison E, Canevari S, Zaffaroni N, Beretta GL.

Biochem Pharmacol. 2012 Jan 1;83(1):27-36. doi: 10.1016/j.bcp.2011.09.021. Epub 2011 Sep 29.

PMID:
21978643
36.

Synthesis, structural, and biological evaluation of bis-heteroarylmaleimides and bis-heterofused imides.

Ferri N, Radice T, Antonino M, Beccalli EM, Tinelli S, Zunino F, Corsini A, Pratesi G, Ragg EM, Gelmi ML, Contini A.

Bioorg Med Chem. 2011 Sep 15;19(18):5291-9. doi: 10.1016/j.bmc.2011.08.016. Epub 2011 Aug 16.

PMID:
21880496
37.

Interplay between Ret and Fap-1 regulates CD95-mediated apoptosis in medullary thyroid cancer cells.

Nicolini V, Cassinelli G, Cuccuru G, Bongarzone I, Petrangolini G, Tortoreto M, Mondellini P, Casalini P, Favini E, Zaffaroni N, Zunino F, Lanzi C.

Biochem Pharmacol. 2011 Oct 1;82(7):778-88. doi: 10.1016/j.bcp.2011.06.037. Epub 2011 Jul 2.

PMID:
21741956
38.

DNA damage persistence as determinant of tumor sensitivity to the combination of Topo I inhibitors and telomere-targeting agents.

Biroccio A, Porru M, Rizzo A, Salvati E, D'Angelo C, Orlandi A, Passeri D, Franceschin M, Stevens MF, Gilson E, Beretta G, Zupi G, Pisano C, Zunino F, Leonetti C.

Clin Cancer Res. 2011 Apr 15;17(8):2227-36. doi: 10.1158/1078-0432.CCR-10-3033. Epub 2011 Feb 25.

39.

Synthesis and biological evaluation of imidazolo[2,1-b]benzothiazole derivatives, as potential p53 inhibitors.

Christodoulou MS, Colombo F, Passarella D, Ieronimo G, Zuco V, De Cesare M, Zunino F.

Bioorg Med Chem. 2011 Mar 1;19(5):1649-57. doi: 10.1016/j.bmc.2011.01.039. Epub 2011 Jan 25.

PMID:
21324703
40.

SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis.

Ritchie JP, Ramani VC, Ren Y, Naggi A, Torri G, Casu B, Penco S, Pisano C, Carminati P, Tortoreto M, Zunino F, Vlodavsky I, Sanderson RD, Yang Y.

Clin Cancer Res. 2011 Mar 15;17(6):1382-93. doi: 10.1158/1078-0432.CCR-10-2476. Epub 2011 Jan 21.

41.

Selective synthesis of gem-chlorofluorinated nitrogen-containing derivatives after superelectrophilic activation in superacid HF/SbF5.

Liu F, Martin-Mingot A, Jouannetaud MP, Bachmann C, Frapper G, Zunino F, Thibaudeau S.

J Org Chem. 2011 Mar 4;76(5):1460-3. doi: 10.1021/jo102225w. Epub 2011 Jan 20.

PMID:
21250710
42.

Proteomic analysis of cellular response to novel proapoptotic agents related to atypical retinoids in human IGROV-1 ovarian carcinoma cells.

Milli A, Perego P, Beretta GL, Corvo A, Righetti PG, Carenini N, Corna E, Zuco V, Zunino F, Cecconi D.

J Proteome Res. 2011 Mar 4;10(3):1191-207. doi: 10.1021/pr100963n. Epub 2011 Jan 18.

PMID:
21142107
43.

Structure-activity relationship study of 16 a-thiocamptothecins: an integrated in vitro and in silico approach.

Samorì C, Beretta GL, Varchi G, Guerrini A, Di Micco S, Basili S, Bifulco G, Riccio R, Moro S, Bombardelli E, Zunino F, Fontana G.

ChemMedChem. 2010 Dec 3;5(12):2006-15. doi: 10.1002/cmdc.201000369.

PMID:
21069656
44.

Pre-clinical and clinical significance of heparanase in Ewing's sarcoma.

Shafat I, Ben-Arush MW, Issakov J, Meller I, Naroditsky I, Tortoreto M, Cassinelli G, Lanzi C, Pisano C, Ilan N, Vlodavsky I, Zunino F.

J Cell Mol Med. 2011 Sep;15(9):1857-64. doi: 10.1111/j.1582-4934.2010.01190.x.

45.

Atomic force microscopy study of DNA conformation in the presence of drugs.

Cassina V, Seruggia D, Beretta GL, Salerno D, Brogioli D, Manzini S, Zunino F, Mantegazza F.

Eur Biophys J. 2011 Jan;40(1):59-68. doi: 10.1007/s00249-010-0627-6. Epub 2010 Sep 30.

PMID:
20882274
46.

Human glioblastoma tumours and neural cancer stem cells express the chemokine CX3CL1 and its receptor CX3CR1.

Erreni M, Solinas G, Brescia P, Osti D, Zunino F, Colombo P, Destro A, Roncalli M, Mantovani A, Draghi R, Levi D, Rodriguez Y Baena R, Gaetani P, Pelicci G, Allavena P.

Eur J Cancer. 2010 Dec;46(18):3383-92. doi: 10.1016/j.ejca.2010.07.022. Epub 2010 Aug 19.

PMID:
20728344
47.

Modulation of cell sensitivity to antitumor agents by targeting survival pathways.

Perego P, Cossa G, Zuco V, Zunino F.

Biochem Pharmacol. 2010 Nov 15;80(10):1459-65. doi: 10.1016/j.bcp.2010.07.030. Epub 2010 Aug 3.

PMID:
20688050
48.

Natural and semisynthetic azaphilones as a new scaffold for Hsp90 inhibitors.

Musso L, Dallavalle S, Merlini L, Bava A, Nasini G, Penco S, Giannini G, Giommarelli C, De Cesare A, Zuco V, Vesci L, Pisano C, Castorina M, Milazzo F, Cervoni ML, Dal Piaz F, De Tommasi N, Zunino F.

Bioorg Med Chem. 2010 Aug 15;18(16):6031-43. doi: 10.1016/j.bmc.2010.06.068. Epub 2010 Jul 1. Erratum in: Bioorg Med Chem. 2010 Dec 15;18(24):8687. Castorina, Massimo [added]; Milazzo, Ferdinando [added]; Cervoni, Maria Luisa [added].

PMID:
20655237
49.

Magnetic tweezers measurements of the nanomechanical properties of DNA in the presence of drugs.

Salerno D, Brogioli D, Cassina V, Turchi D, Beretta GL, Seruggia D, Ziano R, Zunino F, Mantegazza F.

Nucleic Acids Res. 2010 Nov;38(20):7089-99. doi: 10.1093/nar/gkq597. Epub 2010 Jul 3.

50.

Metabolic approach to the enhancement of antitumor effect of chemotherapy: a key role of acetyl-L-carnitine.

Pisano C, Vesci L, Milazzo FM, Guglielmi MB, Foderà R, Barbarino M, D'Incalci M, Zucchetti M, Petrangolini G, Tortoreto M, Perego P, Zuco V, Orlandi A, Passeri D, Carminati P, Cavazza C, Zunino F.

Clin Cancer Res. 2010 Aug 1;16(15):3944-53. doi: 10.1158/1078-0432.CCR-10-0964. Epub 2010 Jun 18.

Supplemental Content

Loading ...
Support Center